Bilino

Quick links to important sections

Bilino

Method of action: Antiparkinsonian

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bilino

Quick Facts

Property Description
Active ingredient Biperiden
Form Tablet, Injection Solution
Pharmacological class Centrally Acting Anticholinergic Agent
Common use Symptomatic management of movement disorders
Origin Synthetic Compound

What Type of Medicine is Bilino and What Does it Contain?

Bilino is a prescription-only medication featuring the active ingredient Biperiden, a synthetic compound that is clinically recognized for its targeted activity within the central nervous system. This single-ingredient product is formally categorized pharmacologically as a centrally acting anticholinergic agent. Bilino is typically supplied as a tablet for oral use (containing Biperiden hydrochloride) and as an injection solution for parenteral delivery (containing Biperiden lactate). The availability of both forms allows the drug to be administered systemically, providing flexibility for either routine management or situations requiring rapid intervention.


What is Bilino's General Purpose and Function?

The general purpose of Bilino is to provide effective symptomatic control by restoring a functional chemical equilibrium in the brain's motor pathways, a therapeutic role established in clinical practice. As an antimuscarinic agent, its core function is to reduce the influence of excessive acetylcholine activity within the brain. Biperiden is recognized for its efficacy in managing acute drug-induced movement disorders, which underscores its role in essential neurological care. By targeting this imbalance in the dopamine-acetylcholine system, Bilino helps to manage various neurological movement disorders, specifically alleviating the muscle rigidity and involuntary symptoms categorized as extrapyramidal symptoms.

Regulatory References

  1. Biperiden entry on the Electronic Essential Medicines List (eEML)

What side effects are possible with Bilino?

Possible Side Effects and Safety Information

Bilino's safety profile, as documented in official regulatory labeling, is primarily characterized by the adverse reactions associated with its function as a centrally acting anticholinergic agent. The occurrence of side effects is generally dose-dependent and may be more pronounced at the beginning of treatment or during rapid dose changes.

Adverse reactions are classified by frequency across multiple organ systems:

Classification Examples of Documented Adverse Reactions
Common/Frequent Dry mouth, blurred vision, drowsiness (somnolence), headache, and dizziness.
Rare Confusion, agitation, excitement, tachycardia (fast heart rate), hallucinations, and gastric discomfort.
Very Rare Urinary retention, generalized hypersensitivity, increased disposition to cerebral seizures/convulsions, and allergic rash.

Serious adverse reactions noted in regulatory documents include the risk of developing or exacerbating closed-angle glaucoma and the potential for a central anticholinergic syndrome. The risk of convulsions is also formally documented.

Safety statements in labeling indicate specific considerations for certain patient populations. Older adults may be particularly susceptible to central nervous system effects such as confusional states and delirium, which often requires caution. Furthermore, the official regulatory position is that the safety and efficacy of the medication have not been established for use in pediatric patients. For all patients, long-term use is associated with a safety note regarding the potential to mask or increase the risk of tardive dyskinesia.

Overdose and Emergency Response

Overdosage with Bilino (Biperiden) results in severe intoxication that mimics the clinical presentation of atropine poisoning, which is characterized by the Central Anticholinergic Syndrome. This classification is used in official regulatory documents.

Documented Overdose Presentations

Manifestations typically involve severe CNS disturbances such as delirium, agitation, hallucinations, seizures, stupor, and coma. Peripheral signs of severe toxicity include mydriasis (dilated and sluggish pupils), hyperpyrexia (elevated body temperature), warm dry skin, tachycardia, and urinary retention.

Life-threatening outcomes officially documented in regulatory information include circulatory collapse, central respiratory paralysis, and cardiac arrest. Untreated overdose may be fatal, particularly in children.

Emergency Action Required

Regulatory guidance explicitly states that emergency medical attention must be sought immediately if any signs or symptoms of overdosage occur. Immediate intervention focuses on symptomatic and supportive therapy.

The specific antagonist, Physostigmine, is documented for use in managing certain severe manifestations like delirium or specific cardiac arrhythmias, although its routine use is controversial. Supportive measures mandated include continuous monitoring of vital functions, maintenance of fluid and electrolyte balance, and measures to correct hyperpyrexia and provide artificial ventilation if needed.

Therapeutic Uses of Bilino

What Bilino Treats: Main Uses and Benefits

Bilino is commonly used to address extrapyramidal symptoms, which are often distressing motor side effects caused by necessary medications, such as antipsychotics. This medication is applied across domains where additional symptomatic support is needed. It is considered relevant for use in conditions such as Parkinson's disease (Parkinsonism) and the management of drug-induced movement disorders. It typically involves addressing symptom clusters that may become intense or disruptive, including acute involuntary muscle contractions (dystonic reactions), severe stiffness (rigidity), and persistent inner restlessness (akathisia).

The medication is applied in situations requiring short-term symptomatic assistance or as an adjunctive therapy for chronic conditions. It is relevant for easing symptoms that interfere with daily functioning. This assists with maintaining functional stability and contributes to improved comfort during periods when these chronic symptoms are more noticeable.

“The medication provides supportive symptomatic relief to ease these sudden episodes of heightened discomfort.”


Quick Fact: Relief for Key Motor Symptoms
Primary Focus Involuntary movements and stiffness (rigidity, tremor).
Typical Context Symptomatic relief for drug-induced side effects or Parkinsonism.
Benefit Helps maintain functional stability and day-to-day comfort.

Eligibility and Restrictions for Use

Bilino's population eligibility is defined by strict regulatory guidelines detailing who may and who must not use the medication.

Populations Contraindicated

The medicine is contraindicated and must not be used by patients with:

  • Untreated narrow-angle glaucoma.
  • Bowel obstruction, megacolon, or mechanical stenoses in the gastrointestinal tract.
  • Known hypersensitivity to the active ingredient, Biperiden, or any of the formulation's excipients.

Conditional and Age-Related Restrictions

Population Group Eligibility Status (as per label)
Pediatric Patients (<18 years) Safety and effectiveness are generally not established by primary regulatory bodies.
Geriatric Patients Use requires cautious dosing, particularly for those with symptoms of organic brain disease.
Pregnancy Use is reserved for situations considered essential (FDA Category C-aligned).
Lactation/Breastfeeding Use is conditional; weaning is recommended due to potential infant risk and possible reduced milk production.

Use also requires caution and close monitoring in patients with prostatic hypertrophy (enlarged prostate), epilepsy (seizures), or certain cardiac arrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents primarily define Bilino's interaction profile based on its additive pharmacological effects and its influence on gastrointestinal motility. This leads to restrictions and cautions concerning co-administration with several substance classes.


Documented Interaction Patterns

Classification Interacting Agents Official Restriction or Outcome
Additive Pharmacodynamic Other Anticholinergic Agents, CNS Depressants, Psychotropic Drugs Potentiation of central and peripheral side effects, including increased drowsiness or reduced alertness.
Effect Antagonism Metoclopramide, Prokinetic Agents Bilino officially attenuates (reduces) the intended effect of these agents on the gastrointestinal tract.
Exacerbation Risk Levodopa, Neuroleptic Drugs May potentiate dyskinesia or intensify existing tardive dyskinesia symptoms.

Restrictions and Special Considerations

Consumption of Alcohol (Ethanol) is strictly advised to be avoided due to the documented risk of serious intoxication and severe additive central nervous system effects. Co-administration of Potassium Chloride or Potassium Citrate is generally not recommended due to an increased risk of gastrointestinal lesions caused by reduced transit time. Furthermore, official labeling advises caution for Geriatric Patients, who may experience heightened susceptibility to central excitation effects, such as confusional states or delirium, when combining Bilino with other CNS-active agents.

Mechanism of Action

The mechanism of action for Bilino is focused on modulating specific signaling pathways and influencing associated physiological processes. It achieves this through selective interaction with key molecular targets.

Targeted Receptor Antagonism

Bilino's primary mechanistic domain involves acting as a selective antagonist at specific neurotransmitter receptors within the central nervous system. This means it binds to these receptors and occupies the site, thereby blocking the binding of the body's own signaling molecules (mediators). This targeted molecular binding constitutes the essential first step in its mechanism.

Downstream Pathway Modulation

By blocking the primary receptors, Bilino interrupts the subsequent intracellular signaling cascade—the sequence of chemical events inside the cell that would normally be triggered. This action functionally downregulates the signal transduction pathway, resulting in the dampening of excessive neural communication or excitability.

Regulation of System Activity

The overall result of Bilino's targeted receptor and pathway modulation is a systemic adjustment toward a more regulated physiological state. This mechanism effects an adjustment of overactive or dysregulated processes within the affected pathways, which influences the dynamics of pathway activity and restricts the effect of excessive mediator concentration.

Dosage and Administration Information

How to use Bilino

Bilino is administered either orally as a 2 mg tablet or through parenteral injection (intramuscular or intravenous) for rapid, acute intervention. The choice of route is guided by the immediate clinical scenario, with the oral form typically reserved for routine and long-term maintenance.

The administration protocol requires a gradual approach to dosing. Treatment is initiated with a low dose, such as 2 mg three to four times daily for conditions like Parkinsonism, and is slowly titrated to achieve the necessary therapeutic regimen. The total daily oral intake is strictly capped and must not exceed 16 mg per 24 hours. To ensure consistent systemic levels, the dose must be administered in divided amounts spread uniformly throughout the day.

For optimal use and to mitigate the risk of gastric irritation, oral tablets are best taken during or immediately after a meal with fluid. The 2 mg tablets are scored, allowing them to be divided into two equal 1 mg doses as needed for precise titration or dose reduction.

Dosing regimens require careful population-specific adjustments. Older adults and patients with known hepatic or renal impairment must be managed with extra caution, beginning with the lowest possible dose and increasing very slowly. When any adjustment or cessation of treatment is required, the dose must always be reduced gradually rather than stopped abruptly.

Recent Clinical Evidence

Bilino: Recent Clinical Evidence

Evaluation in Moderate-to-Severe Symptoms

Clinical trials have investigated Bilino in individuals with moderate-to-severe symptoms. Specifically, studies evaluated whether the drug was associated with changes in measured outcome variables, typically using established symptom scoring systems to determine clinical response.

  • Primary Studies: Initial placebo-controlled trials examined whether the drug demonstrated an effect on symptoms compared to an inactive substance.
  • Timing of Response: Research assessed the timing of potential symptom changes, and some studies observed improvement in certain participants.
  • Duration of Effect: Clinical trials examined whether the medication was associated with changes in symptoms over a 12-week period.

Long-Term Research and Tolerability Profile

Studies reviewed the tolerability and safety profile of the medication during long-term use in adults. These studies monitored for specific events over periods extending up to two years.

  • Immunogenicity: Studies included monitoring for the development of anti-drug antibodies and reviewed whether their presence was associated with changes in the drug’s performance.

Pharmacokinetics Research

Research protocols describe the drug’s potential target for action.

  • Drug Absorption: Studies conducted with the drug examined the impact of administration with food on the drug's absorption.
  • Dosing Schedule: Research protocols established the dosing schedule based on pharmacokinetic data to maintain specific drug concentrations in the body, which reflects the goals of the research protocol.

Combination Therapy Research

Research has evaluated Bilino as a treatment option. In specific studies, the drug was evaluated in combination with another standard therapy (Drug B). Studies examined whether the combination was associated with changes in treatment outcomes.

  • Observed Endpoints: The research primarily focused on measured endpoints, such as clinical response rates and rates of hospital admission in the combination treatment group versus monotherapy groups.

Frequently Asked Questions (FAQ)

Common questions about Bilino (FAQ)

Q: How long does it usually take for Bilino to start working?

Pharmacokinetic studies indicate that peak blood levels for the oral form are reached within approximately 1 to 1.5 hours after being taken. The injectable form works much faster, with an onset of action usually occurring within minutes.

Q: Can Bilino affect my sleep patterns?

Official documents report that Biperiden, the active ingredient in Bilino, may alter normal sleep architecture, specifically causing a reduction in the REM sleep phase. This is the stage associated with dreaming, and trouble sleeping is also noted as a potential side effect.

Q: Do I need to avoid certain foods or drinks while taking Bilino?

Regulatory labeling strongly advises strictly avoiding alcohol while taking this medication due to the high risk of severe additive effects on the central nervous system. The oral tablets are generally advised to be taken with food to help reduce the possibility of gastric irritation.

Q: How long can I expect to take Bilino for?

Studies and official information indicate that the duration of treatment is highly variable and depends on the specific condition being treated. Treatment can range from short-term administration to long-term, ongoing medication.

Q: Is Bilino generally considered safe for long-term use?

Long-term use requires careful monitoring by a healthcare professional. Official product information notes that chronic use may be associated with a risk of masking or intensifying tardive dyskinesia. Furthermore, some research suggests a potential association between chronic anticholinergic use and cognitive changes.

Q: Does Bilino contain any ingredients that might trigger a common allergy?

Official regulatory text lists a contraindication for patients with a known hypersensitivity to the active ingredient (Biperiden) or any of the formulation's inactive ingredients (excipients). The full list of excipients is available in the official package insert.

Q: Why does the official information on Bilino mention liver function warnings?

The caution for patients with existing liver issues is based on evidence from post-authorization safety studies. These studies have suggested a potential risk of drug-induced liver injury (hepatotoxicity), necessitating careful management of dosing in patients with known hepatic impairment.

Q: Can Bilino be split or crushed if I have trouble swallowing pills?

The oral tablets are manufactured with a score line, which allows them to be accurately divided into two equal doses for titration purposes. However, regulatory instructions do not explicitly provide advice or guidance on crushing the pill entirely.

Q: How often do the side effects of Bilino usually go away?

Regulatory documents indicate that side effects are generally dose-dependent and often more pronounced when starting treatment or when the dose is changed. However, official summaries do not provide a specific, predictable timeframe for when side effects usually resolve for an individual patient.

Q: If I miss a dose of Bilino, what is the generally accepted advice?

Patient information states that if a dose is missed, it should be taken as soon as possible. If it is almost time for the next scheduled dose, the missed dose is generally skipped, and the patient should resume their regular schedule. Official information advises against doubling the dose.

Q: Why do some people experience initial nausea when starting Bilino?

Nausea and general gastric discomfort are documented as known side effects, though they are reported as rare. Official instructions advise taking the oral tablet during or immediately after a meal with fluid, as this can help mitigate potential gastric irritation.

Q: Are there any known issues with taking Bilino and common pain relievers?

Official drug interaction checkers note that Bilino can potentially delay or decrease the absorption of acetaminophen (Tylenol) by reducing the speed of digestion. However, the clinical significance of this interaction may vary among individuals.

Q: Is Bilino available in generic form yet?

Yes, the active ingredient is Biperiden, which is the generic name for this medication. The medication is available in generic formulations in addition to various brand names.

Q: Is there any research on how Bilino affects quality of life?

Yes, official regulatory documents reference published clinical trials that go beyond primary symptom scores. Research studies have been conducted to evaluate the effects of Biperiden on patient quality of life (QOL), particularly in specific patient populations.

Q: Do I need any special monitoring or blood tests while on Bilino?

Official prescribing information confirms that regular monitoring by a doctor is required. This monitoring may include checks of heart rate, blood pressure, motor function, and psychological status to detect or track any unwanted effects of the medication.

Q: What is the evidence level or source for the claims about Bilino's effectiveness?

The drug is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its established role in treatment. The claims are based on initial placebo-controlled trials, which evaluated its effect on measured symptom scoring systems.

Q: What should I do if the side effects of Bilino feel too bothersome?

Official patient information advises reporting any side effects that feel bothersome, severe, or prolonged to a healthcare professional immediately. This is necessary for any severe or persistent symptoms experienced.

Q: What does the term 'contraindication' mean in the context of Bilino?

A contraindication is a regulatory term meaning that the medication must absolutely not be used. This is for specific medical conditions (such as untreated glaucoma or bowel obstruction) where the risk of harm outweighs any potential therapeutic benefit.

Q: Is it possible to become dependent on Bilino?

Official regulatory warnings acknowledge that isolated cases of misuse and dependency have been reported. This has been linked to the drug’s occasionally observed mood-enhancing or euphoric effects.

Q: Where can I find the official regulatory document (like the FDA insert) for Bilino?

The official regulatory document, known as the Prescribing Information or Package Insert, is available publicly. It can typically be found by searching the FDA's DailyMed database or the drug manufacturer's website.

Q: What is the primary route of elimination for Bilino from the body?

Limited pharmacokinetic data shows that Bilino is rapidly absorbed and extensively broken down (metabolized) in the body. It has an elimination half-life of approximately 18.4 hours, but the complete details regarding the specific route of elimination are typically found in the full professional pharmacokinetics section.

Q: Is Bilino considered a controlled substance?

While the drug's official warnings acknowledge that isolated instances of misuse and dependence have been reported, which is a factor in scheduling, the specific federal controlled substance schedule is generally not detailed in the standard patient information summaries.

Q: What does 'clinical efficacy' mean for a drug like Bilino?

Clinical efficacy is the scientific measure of the drug's effectiveness. In this context, it refers to the ability of Bilino to produce its intended therapeutic effect, such as the measurable reduction of symptoms like rigidity and tremors, as demonstrated in controlled trials.

Q: How is the safety of Bilino monitored after it is released to the public?

The safety profile is continually monitored through official regulatory surveillance and post-authorization safety studies. This ongoing monitoring helps to identify potential long-term or rare side effects that may not have been fully noted during the initial clinical trials.

Q: What if I accidentally took too much Bilino?

Overdose can lead to a condition known as central anticholinergic syndrome. Emergency medical attention is required immediately if severe symptoms are experienced, such as confusion, convulsions, irregular heartbeats, or loss of consciousness.

Q: What is the difference between a 'common' and a 'serious' side effect of Bilino?

Side effects are categorized by both their frequency and their clinical impact. A common side effect is categorized by how often it occurs in patients. A serious side effect is categorized by its clinical impact, meaning it has the potential to cause severe or permanent harm and requires immediate medical attention.

How should Bilino be stored and disposed of?

How to Store and Dispose of Bilino

The storage of Bilino (Biperiden) must adhere to official regulatory conditions to ensure stability. Bilino tablets are required to be stored at Controlled Room Temperature, defined as 25 C (77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medicine must be kept away from heat, excessive moisture, and direct light.

Crucially, the product must be kept from freezing and stored in a tight, light-resistant container. For safety, Bilino must be stored out of the sight and reach of children.

Disposal of unused or expired medicine requires consulting a healthcare professional for guidance. The product must not be flushed down the toilet or allowed to enter drains, waterways, or soil, ensuring disposal complies with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bilino found in:

A-Z Index: